Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90

Nature Chemical Biology

Volumn 7, Issue 11, 2011, Pages 818-826

  Moulick, Kamalika ^a   Ahn, James H ^a   Zong, Hongliang ^b   Rodina, Anna ^a   Cerchietti, Leandro ^b   Gomes DaGama, Erica M ^a   Caldas Lopes, Eloisi ^a   Beebe, Kristin ^c   Perna, Fabiana ^a   Hatzi, Katerina ^b   Vu, Ly P ^a   Zhao, Xinyang ^a   Zatorska, Danuta ^a   Taldone, Tony ^a   Smith Jones, Peter ^a   Alpaugh, Mary ^a   Gross, Steven S ^b   Pillarsetty, Nagavarakishore ^a   Ku, Thomas ^a   Lewis, Jason S ^a   Larson, Steven M ^a   Levine, Ross ^a   Erdjument Bromage, Hediye ^a   Guzman, Monica L ^b   Nimer, Stephen D ^a   Melnick, Ari ^b   Neckers, Len ^c   Chiosis, Gabriela ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90; ONCOPROTEIN; PU H 71; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BIOINFORMATICS; CANCER CELL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; MOLECULAR INTERACTION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 80054851888     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.670     Document Type: Article

References (46)

1. Ley, T.J. et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66-72 (2008).
2. Parsons, D.W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
3. Hanash, S. & Taguchi, A. The grand challenge to decipher the cancer proteome. Nat. Rev. Cancer 10, 652-660 (2010).
4. Kolch, W. & Pitt, A. Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat. Rev. Cancer 10, 618-629 (2010).
5. Nomura, D.K., Dix, M.M. & Cravatt, B.F. Activity-based protein profiling for biochemical pathway discovery in cancer. Nat. Rev. Cancer 10, 630-638 (2010).
6. Brehme, M. et al. Charting the molecular network of the drug target Bcr-Abl. Proc. Natl. Acad. Sci. USA 106, 7414-7419 (2009).
7. Ashman, K. & Villar, E.L. Phosphoproteomics and cancer research. Clin. Transl. Oncol. 11, 356-362 (2009).
8. Zuehlke, A. & Johnson, J.L. Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers 93, 211-217 (2010).
9. Workman, P., Burrows, F., Neckers, L. & Rosen, N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. NY Acad. Sci. 1113, 202-216 (2007). (Pubitemid 350015011)
10. Kamal, A. et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407-410 (2003). (Pubitemid 37187270)
11. Janin, Y.L. ATPase inhibitors of heat-shock protein 90, second season. Drug Discov. Today 15, 342-353 (2010).
12. Tsaytler, P.A., Krijgsveld, J., Goerdayal, S.S., Rudiger, S. & Egmond, M.R. Novel Hsp90 partners discovered using complementary proteomic approaches. Cell Stress Chaperones 14, 629-638 (2009).
13. da Rocha Dias, S. et al. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 65, 10686-10691 (2005). (Pubitemid 41713335)
14. Grbovic, O.M. et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl. Acad. Sci. USA 103, 57-62 (2006). (Pubitemid 43076104)
15. Taldone, T. & Chiosis, G. Purine-scaffold hsp90 inhibitors. Curr. Top. Med. Chem. 9, 1436-1446 (2009).
16. Dezwaan, D.C. & Freeman, B.C. HSP90: the Rosetta stone for cellular protein dynamics? Cell Cycle 7, 1006-1012 (2008). (Pubitemid 351679833)
17. Ren, R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 5, 172-183 (2005). (Pubitemid 40314949)
18. Burke, B.A. & Carroll, M. BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia. Leukemia 24, 1105-1112 (2010).
19. McClellan, A.J. et al. Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 131, 121-135 (2007). (Pubitemid 47498528)
20. Carayol, N. et al. Critical roles for mTORC2-and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc. Natl. Acad. Sci. USA 107, 12469-12474 (2010).
21. Nobukuni, T., Kozma, S.C. & Thomas, G. hvps34, an ancient player, enters a growing game: mTOR Complex1/S6K1 signaling. Curr. Opin. Cell Biol. 19, 135-141 (2007). (Pubitemid 46386413)
22. McCubrey, J.A. et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22, 708-722 (2008). (Pubitemid 351565619)
23. Häcker, H. & Karin, M. Regulation and function of IKK and IKK-related kinases. Sci. STKE 2006, re13 (2006).
24. Mihailovic, T. et al. Protein kinase D2 mediates activation of nuclear factor kappaB by Bcr-Abl in Bcr-Abl+ human myeloid leukemia cells. Cancer Res. 64, 8939-8944 (2004). (Pubitemid 39665501)
25. Hendriks, R.W. & Kersseboom, R. Involvement of SLP-65 and Btk in tumor suppression and malignant transformation of pre-B cells. Semin. Immunol. 18, 67-76 (2006). (Pubitemid 43238338)
26. Mahajan, S. et al. Transcription factor STAT5A is a substrate of Brutons tyrosine kinase in B cells. J. Biol. Chem. 276, 31216-31228 (2001). (Pubitemid 37384990)
27. Oda, A., Wakao, H. & Fujita, H. Calpain is a signal transducer and activator of transcription (STAT) 3 and STAT5 protease. Blood 99, 1850-1852 (2002). (Pubitemid 34533062)
28. Si, J. & Collins, S.J. Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation. Cancer Res. 68, 3733-3742 (2008).
29. Salgia, R. et al. Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene 11, 1149-1155 (1995).
30. Le, Y. et al. FAK silencing inhibits leukemogenesis in BCR/ABL-transformed hematopoietic cells. Am. J. Hematol. 84, 273-278 (2009).
31. Sawyers, C.L. The role of myc in transformation by Bcr-Abl. Leuk. Lymphoma 11, 45-46 (1993). (Pubitemid 23274135)
32. Naka, K. et al. TGF-beta-FOXO signaling maintains leukemia-initiating cells in chronic myeloid leukemia. Nature 463, 676-680 (2010).
33. Bedford, M.T. & Clarke, S.G. Protein arginine methylation in mammals: who, what, and why. Mol. Cell 33, 1-13 (2009).
34. Maloney, A. et al. Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 67, 3239-3253 (2007). (Pubitemid 46724862)
35. Jaganathan, S., Yue, P. & Turkson, J. Enhanced sensitivity of pancreatic cancer cells to concurrent inhibition of aberrant signal transducer and activator of transcription 3 and epidermal growth factor receptor or Src. J. Pharmacol. Exp. Ther. 333, 373-381 (2010).
36. Apsel, B. et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691-699 (2008).
37. Deininger, M.W. & Druker, B.J. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol. Rev. 55, 401-423 (2003). (Pubitemid 37013211)
38. Katzav, S. Flesh and blood: the story of Vav1, a gene that signals in hematopoietic cells but can be transforming in human malignancies. Cancer Lett. 255, 241-254 (2007). (Pubitemid 47268643)
39. Pratt, W.B., Morishima, Y. & Osawa, Y. The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J. Biol. Chem. 283, 22885-22889 (2008).
40. de Groot, R.P., Raaijmakers, J.A., Lammers, J.W., Jove, R. & Koenderman, L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 94, 1108-1112 (1999). (Pubitemid 29361844)
41. An, W.G., Schulte, T.W. & Neckers, L.M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 11, 355-360 (2000). (Pubitemid 30619563)
42. Klejman, A. et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J. 21, 5766-5774 (2002). (Pubitemid 35315274)
43. Xu, D. & Qu, C.K. Protein tyrosine phosphatases in the JAK/STAT pathway. Front. Biosci. 13, 4925-4932 (2008). (Pubitemid 351599646)
44. Lim, C.P. & Cao, X. Structure, function and regulation of STAT proteins. Mol. Biosyst. 2, 536-550 (2006). (Pubitemid 44583902)
45. Paukku, K. & Silvennoinen, O. STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5. Cytokine Growth Factor Rev. 15, 435-455 (2004). (Pubitemid 39550454)
46. Rix, U. & Superti-Furga, G. Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 5, 616-624 (2009).